Welcome to our dedicated page for LB Pharmaceuticals SEC filings (Ticker: LBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The LB Pharmaceuticals Inc (LBRX) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission, alongside AI-assisted summaries to help interpret the information. As a clinical-stage biopharmaceutical company focused on schizophrenia, bipolar depression, and other neuropsychiatric diseases, LB Pharmaceuticals uses SEC filings to report on its financial condition, clinical development plans, corporate governance, and material agreements.
Core documents for LBRX include its registration statement on Form S-1/A, which describes the company’s business, risk factors, and the role of its lead product candidate, LB-102. This filing outlines LB-102’s status as a Phase 3–ready oral, small-molecule drug and a methylated derivative of amisulpride, and explains the company’s focus on neuropsychiatric indications such as acute schizophrenia and bipolar depression. Periodic reports and earnings-related Form 8-K filings provide condensed balance sheets, statements of operations, and narrative updates on research and development and general and administrative expenses.
Other current reports on Form 8-K document material corporate events, including lease amendments for additional office space, appointments of senior executives, and press releases announcing quarterly financial results. These filings also confirm that LB Pharmaceuticals’ common stock is listed on The Nasdaq Stock Market LLC under the ticker LBRX and that the company is incorporated in Delaware.
On Stock Titan, users can review these filings in chronological order and use AI-powered summaries to quickly understand key points from lengthy documents, such as the implications of clinical trial disclosures, changes in operating expenses, or the significance of material agreements. Access to insider transaction reports on Form 4, annual reports on Form 10-K, and quarterly reports on Form 10-Q, when filed, can further support analysis of LBRX’s progress as a clinical-stage biopharmaceutical issuer.
LB Pharmaceuticals Inc. is a late-stage biopharmaceutical company focused on neuropsychiatric disorders, built around its lead candidate LB-102, a novel, methylated benzamide antipsychotic. LB-102 is designed to improve on amisulpride by enhancing blood–brain barrier penetration, enabling lower, once-daily dosing while preserving a selective D2/D3/5-HT7 receptor profile.
The company reported positive results from a four-week Phase 2 trial in acute schizophrenia, where LB-102 achieved statistically significant reductions in PANSS total scores across 50 mg, 75 mg, and 100 mg doses, with responder rates up to 78.3% and a tolerability profile characterized by low rates of EPS (including akathisia), minimal sedation, and few gastrointestinal effects. Exploratory analyses suggested benefits on negative symptoms and cognition using the CogState battery, with effect sizes increasing by dose and mediation analyses indicating a primarily direct cognitive effect.
LB Pharmaceuticals has initiated a six-week Phase 3 schizophrenia trial (NOVA-2) in the United States comparing 50 mg and 100 mg LB-102 versus placebo, targeting approximately 460 patients, and expects topline data in the second half of 2027. It is also running or planning Phase 2 programs in bipolar 1 depression (ILLUMINATE-1, topline data expected in the first quarter of 2028) and adjunctive major depressive disorder, and is developing a long-acting injectable formulation to address adherence. The company holds global rights to LB-102 and intends to retain U.S. commercialization while evaluating ex-U.S. collaborations.
LB Pharmaceuticals reported another net loss for 2025 but with a much stronger balance sheet and advancing clinical pipeline. Net loss for 2025 was about $25.2 million, a sharp improvement from $63.1 million in 2024, as operating loss narrowed and non-operating income increased.
Cash, cash equivalents and investments were $295.2 million as of December 31, 2025, compared with $28.0 million a year earlier, supported by an IPO and a recent $100 million private placement. The company expects this to fund operations into the second quarter of 2029.
Operationally, LB reported positive Phase 2 results for LB-102 in acute schizophrenia and has started the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression, with a Phase 2 adjunctive MDD study planned for early 2027.
LB Pharmaceuticals Inc reported that director Zachary Prensky plans to retire from the Board and will not stand for reelection at the company’s 2026 annual meeting of stockholders. His current term will end at the conclusion of that meeting, and he will continue serving on the Board and the Nominating and Corporate Governance Committee until then.
The company stated that Mr. Prensky’s decision was not due to any disagreement regarding operations, policies, or practices. After his Board service ends, he is expected to provide consulting services under an amended Transition, Separation, and Consulting Agreement, which allows his unvested stock options to continue vesting during the agreement term.
LB Pharmaceuticals director Robert A. Lenz received a grant of stock options for 20,000 shares of common stock. The options have an exercise price of $23.78 per share and expire on March 5, 2036. They vest in three equal annual installments on March 6, 2027, March 6, 2028, and March 6, 2029, contingent on continued service. Following this grant, he holds 20,000 derivative securities directly.
LB PHARMACEUTICALS INC director Robert A. Lenz filed an initial ownership report on Form 3. This filing establishes his status as a director and formally records his position as an insider of the company, but it does not list any specific share transactions or derivative holdings.
LB Pharmaceuticals Inc appointed Robert A. Lenz, M.D., Ph.D., to its Board of Directors as a Class I director, with a term running through the 2026 annual stockholder meeting, and named him to the Nominating and Corporate Governance Committee.
Under the non-employee director compensation policy, Dr. Lenz will receive a $40,000 annual board retainer, a $5,000 annual committee retainer, an initial option to purchase 20,000 shares vesting over three years, and annual options for 10,000 shares vesting by the next annual meeting.
The Board also promoted Gad Soffer to Chief Operating and Business Officer, with at-will employment, an annual base salary of $505,000, and eligibility for an annual bonus targeted at 40% of base salary. The company describes itself as a late-stage biopharmaceutical firm advancing lead candidate LB-102 for multiple neuropsychiatric indications.
LB Pharmaceuticals Inc. received an updated ownership report from RA Capital-affiliated investors. As of December 31, 2025, RA Capital Healthcare Fund, L.P. directly holds 2,208,604 shares of LB Pharmaceuticals common stock, representing 8.7% of the outstanding shares, based on 25,299,102 shares reported outstanding as of November 6, 2025.
RA Capital Management, L.P. acts as investment adviser to the fund, and Peter Kolchinsky and Rajeev Shah are controlling persons of the general partner entities. The filers state the securities are not held for the purpose of changing or influencing control of LB Pharmaceuticals and disclaim group status and beneficial ownership beyond what is required for Section 13(d) reporting.
Deep Track Capital and affiliates updated their ownership filing for LB Pharmaceuticals Inc. after participating in a private placement. Following the transaction, Deep Track Capital, LP and David Kroin report beneficial ownership of 3,352,804 shares of common stock, representing 11.7% of the company.
The issuer sold 3,306,571 common shares and pre-funded warrants to purchase up to 1,417,107 additional shares in the private placement. Deep Track Biotechnology Master Fund, Ltd holds 2,686,138 shares, or 9.4% of the class, and Deep Track Special Opportunities Fund, LP holds 666,666 shares, or 2.3%. The pre-funded warrants have a $0.0001 exercise price and are subject to a 9.99% beneficial ownership cap, so the reporting persons currently disclaim beneficial ownership of the underlying warrant shares. LB Pharmaceuticals agreed to register the resale of the purchased shares and warrant shares on a Form S-1 and to keep that registration effective under specified conditions.
LB Pharmaceuticals Inc. reported insider purchases of pre-funded warrants by Deep Track-affiliated funds. On February 6, 2026, Deep Track Biotechnology Master Fund, Ltd. acquired 378,444 pre-funded warrants, and Deep Track Special Opportunities Fund, LP acquired 93,925 pre-funded warrants, each at $21.1699 per warrant.
The pre-funded warrants are exercisable immediately at an exercise price of $0.0001 per share of common stock and do not expire. Their terms cap beneficial ownership at 9.99% of LB Pharmaceuticals’ outstanding common stock, preventing exercises that would put the holder and its affiliates above that threshold. Deep Track Capital, LP and David Kroin are reporting persons and state they may be deemed beneficial owners only to the extent of their pecuniary interests.
LB Pharmaceuticals Inc entered into a private placement financing, agreeing to sell 3,306,571 common shares and pre-funded warrants for up to 1,417,107 additional shares at prices around $21.17 per share, for estimated gross proceeds of about $100 million.
The company plans to use the net proceeds mainly to fund a Phase 2 trial of LB-102 as an adjunctive treatment for major depressive disorder, as well as for working capital and general corporate purposes. The multi-center, six-week trial is expected to enroll about 380 patients across roughly 50 sites in the U.S. and Europe.